Top

Respiratory Research

Published in:

01-12-2020 | Pneumonia | Research

FluA-p score: a novel prediction rule for mortality in influenza A-related pneumonia patients

Authors: Liang Chen, Xiudi Han, Yan Li Li, Chunxiao Zhang, Xiqian Xing

Published in: Respiratory Research | Issue 1/2020

Abstract

Background

The pneumonia severity index (PSI) and the CURB-65 (confusion, urea, respiratory rate, blood pressure, age ≥ 65 years) score have been shown to predict mortality in community-acquired pneumonia. Their ability to predict influenza-related pneumonia, however, is less well-established.

Methods

A total of 693 laboratory-confirmed FluA-p patients diagnosed between Jan 2013 and Dec 2018 and recruited from five teaching hospitals in China were included in the study. The sample included 494 patients in the derivation cohort and 199 patients in the validation cohort. The prediction rule was established based on independent risk factors for 30-day mortality in FluA-p patients from the derivation cohort.

Results

The 30-day mortality of FluA-p patients was 19.6% (136/693). The FluA-p score was based on a multivariate logistic regression model designed to predict mortality. Results indicated the following significant predictors (regression statistics and point contributions toward total score in parentheses): blood urea nitrogen > 7 mmol/L (OR 1.604, 95% CI 1.150–4.492, p = 0.040; 1 points), pO₂/F_iO₂ ≤ 250 mmHg (OR 2.649, 95% CI 1.103–5.142, p = 0.022; 2 points), cardiovascular disease (OR 3.967, 95% CI 1.269–7.322, p < 0.001; 3 points), arterial PH < 7.35 (OR 3.959, 95% CI 1.393–7.332, p < 0.001; 3 points), smoking history (OR 5.176, 95% CI 2.604–11.838, p = 0.001; 4 points), lymphocytes < 0.8 × 10⁹/L (OR 8.391, 95% CI 3.271–16.212, p < 0.001; 5 points), and early neurominidase inhibitor therapy (OR 0.567, 95% CI 0.202–0.833, p = 0.005; − 2 points). Seven points was used as the cut-off value for mortality risk stratification. The model showed a sensitivity of 0.941, a specificity of 0.762, and overall better predictive performance than the PSI risk class (AUROC = 0.908 vs 0.560, p < 0.001) and the CURB-65 score (AUROC = 0.908 vs 0.777, p < 0.001).

Conclusions

Our results showed that a FluA-p score was easy to derive and that it served as a reliable prediction rule for 30-day mortality in FluA-p patients. The score could also effectively stratify FluA-p patients into relevant risk categories and thereby help treatment providers to make more rational clinical decisions.

Available only for authorised users

Neuzil KM, Bresee JS, de la Hoz F, Johansen K, Karron RA, Krishnan A, et al. Data and product needs for influenza immunization programs in low- and middle-income countries: rationale and main conclusions of the WHO preferred product characteristics for next-generation influenza vaccines. Vaccine. 2017;35:5734–47 https://doi.org/10.1016/j.vaccine.2017.08.088.PubMedCrossRef

Spreeuwenberg P, Kroneman M, Paget J. Reassessing the global mortality burden of the 1918 influenza pandemic. Am J Epidemiol. 2018;187:2561–7 https://doi.org/10.1093/aje/kwy191.PubMedCrossRef

Nielsen J, Vestergaard LS, Richter L, Schmid D, Bustos N, Asikainen T, et al. European all-cause excess and influenza-attributable mortality in the 2017/18 season: should the burden of influenza B be reconsidered? Clin Microbiol Infect. 2019;25:1266–76 https://doi.org/10.1016/j.cmi.2019.02.011.PubMedCrossRef

Vestergaard LS, Nielsen J, Krause TG, Espenhain L, Tersago K, Bustos Sierra N, et al. Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017. Euro Surveill. 2017;22:30506 https://doi.org/10.2807/1560-7917.ES.2017.22.14.30506.PubMedPubMedCentralCrossRef

Shang M, Blanton L, Brammer L, Olsen SJ, Fry AM. Influenza-associated pediatric deaths in the United States, 2010-2016. Pediatrics. 2018;141:e20172918 https://doi.org/10.1542/peds.2017-2918.PubMedCrossRef

Ly S, Arashiro T, Ieng V, Tsuyuoka R, Parry A, Horwood P, et al. Establishing seasonal and alert influenza thresholds in Cambodia using the WHO method: implications for effective utilization of influenza surveillance in the tropics and subtropics. Western Pac Surveill Response J. 2017;8:22–32 https://doi.org/10.5365/WPSAR.2017.8.1.002.PubMedPubMedCentralCrossRef

Gentile A, Paget J, Bellei N, Torres JP, Vazquez C, Laguna-Torres VA, et al. Influenza in Latin America: a report from the global influenza initiative (GII). Vaccine. 2019;37:2670–8 https://doi.org/10.1016/j.vaccine.2019.03.081.PubMedCrossRef

Peteranderl C, Herold S, Schmoldt C. Human influenza virus infections. Semin Respir Crit Care Med. 2016;37:487–500 https://doi.org/10.1055/s-0036-1584801.PubMedPubMedCentralCrossRef

Kumar V. Influenza in Children. Indian J Pediatr. 2017;84:139–43 https://doi.org/10.1007/s12098-016-2232-x.PubMedCrossRef

10.

Almond MH, McAuley DF, Wise MP, Griffiths MJ. Influenza-related pneumonia. Clin Med (Lond). 2012;12:67–70 https://doi.org/10.7861/clinmedicine.12-1-67.CrossRef

11.

Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58:377–82 https://doi.org/10.1136/thorax.58.5.377.PubMedPubMedCentralCrossRef

12.

Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243–50 https://doi.org/10.1056/NEJM199701233360402.PubMedCrossRef

13.

Commons RJ, Denholm J. Triaging pandemic flu: pneumonia severity scores are not the answer. Int J Tuberc Lung Dis. 2012;16:670–3 https://doi.org/10.5588/ijtld.11.0446.PubMedCrossRef

14.

Mulrennan S, Tempone SS, Ling IT, William SH, Gan GC, Murray RJ, et al. Pandemic influenza (H1N1) 2009 pneumonia: CURB-65 score for predicting severity and nasopharyngeal sampling for diagnosis are unreliable. PLoS One. 2010;5:e12849 https://doi.org/10.1371/journal.pone.0012849.PubMedPubMedCentralCrossRef

15.

Cunha BA, Pherez FM, Schoch P. Diagnostic importance of relative lymphopenia as a marker of swine influenza (H1N1) in adults. Clin Infect Dis. 2009;49:1454–6 https://doi.org/10.1086/644496.PubMedCrossRef

16.

Ho YC, Wang JL, Wang JT, Wu UI, Chang CW, Wu HS, et al. Prognostic factors for fatal adult influenza pneumonia. J Inf Secur. 2009;58:439–45 https://doi.org/10.1016/j.jinf.2009.03.007.

17.

Chen L, Zhou F, Li H, Xing X, Han X, Wang Y, et al. Disease characteristics and management of hospitalised adolescents and adults with community-acquired pneumonia in China: a retrospective multicentre survey. BMJ Open. 2018;8:e018709 https://doi.org/10.1136/bmjopen-2017-018709.PubMedPubMedCentralCrossRef

18.

Jain S, Self WH, Wunderink RG, Fakhran S, Balk R, Bramley AM, et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med. 2015;373:415–27 https://doi.org/10.1056/NEJMoa1500245.PubMedPubMedCentralCrossRef

19.

McGeer A, Green KA, Plevneshi A, Shigayeva A, Siddiqi N, Raboud J, et al. Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. Clin Infect Dis. 2007;45:1568–75 https://doi.org/10.1086/523584.PubMedCrossRef

20.

Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the management of community-acquired pneumonia in adults. Clin Infect Diss. 2007;44(Suppl 2):S27–72 https://doi.org/10.1086/511159.CrossRef

21.

Lim WS, Baudouin SV, George RC, Hill AT, Jamieson C, Le Jeune I, et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax. 2009;64(Suppl 3):iii1–55 https://doi.org/10.1136/thx.2009.121434.PubMedCrossRef

22.

Chalmers JD, Singanayagam A, Akram AR, Mandal P, Short PM, Choudhury G, et al. Severity assessment tools for predicting mortality in hospitalised patients with community-acquired pneumonia. Thorax. 2010;65:878–83 https://doi.org/10.1136/thx.2009.133280.PubMedCrossRef

23.

Buising KL, Thursky KA, Black JF, MacGregor L, Street AC, Kennedy MP, et al. A prospective comparison of severity scores for identifying patients with severe community-acquired pneumonia: reconsidering what is meant by severe pneumonia. Thorax. 2006;61:419–24 https://doi.org/10.1136/thx.2005.051326.PubMedPubMedCentralCrossRef

24.

Capelastegui A, Espana PP, Quintana JM, Areitio I, Gorordo I, Egurrola M, et al. Validation of a predictive rule for the management of community-acquired pneumonia. Eur Respir J. 2006;27:151–7 https://doi.org/10.1183/09031936.06.00062505.PubMedCrossRef

25.

Riquelme R, Jimenez P, Videla AJ, Lopez H, Chalmers J, Singanayagam A, et al. Predicting mortality in hospitalised patients with 2009 H1N1 influenza pneumonia. Int J Tuberc Lung Dis. 2011;15:542–6 https://doi.org/10.5588/ijtld.10.0539.PubMedCrossRef

26.

Singanayagam A, Singanayagam A, Wood V, Chalmers JD. Factors associated with severe illness in pandemic 2009 influenza a (H1N1) infection: implications for triage in primary and secondary care. J Inf Secur. 2011;63:243–51 https://doi.org/10.1016/j.jinf.2011.07.014.

27.

Shi SJ, Li H, Liu M, Liu YM, Zhou F, Liu B, et al. Mortality prediction to hospitalised patients with influenza pneumonia: PO₂ /F_iO₂ combined lymphocyte count is the answer. Clin Respir J. 2017;11:352–60 https://doi.org/10.1111/crj.12346.PubMedCrossRef

28.

Guo L, Wei D, Zhang X, Wu Y, Li Q, Zhou M, et al. Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score. Front Microbiol. 2019;10:2752 https://doi.org/10.3389/fmicb.2019.02752.PubMedPubMedCentralCrossRef

29.

Chen C, Chen J, Huang JA. Persistence of lymphocytopenia with CT abnormalities among patients with critical H7N9 swine-origin influenza A virus infection. Jpn J Radiol. 2015;33:657–62 https://doi.org/10.1007/s11604-015-0476-4.PubMedPubMedCentralCrossRef

30.

Bellelli V, d'Ettorre G, Celani L, Borrazzo C, Ceccarelli G, Venditti M. Clinical significance of lymphocytopenia in patients hospitalised with pneumonia caused by influenza virus. Crit Care. 2019;23:330 https://doi.org/10.1186/s13054-019-2608-1.PubMedPubMedCentralCrossRef

31.

Gonzalez Y, Juárez E, Carranza C, Sada E, Pedraza-Sánchez S, Torres M. Diminished effector and memory CD8+ circulating T lymphocytes in patients with severe influenza caused by the AH1N1 pdm09 virus. Virology. 2017;500:139–48 https://doi.org/10.1016/j.virol.2016.10.016.PubMedCrossRef

32.

Fox A, Le NM, Horby P, van Doorn HR, Nguyen VT, Nguyen HH, et al. Severe pandemic H1N1 2009 infection is associated with transient NK and T deficiency and aberrant CD8 responses. PLoS One. 2012;7:e31535 https://doi.org/10.1371/journal.pone.0031535.PubMedPubMedCentralCrossRef

33.

To KK, Hung IF, Li IW, Lee KL, Koo CK, Yan WW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis. 2010;50:850–9 https://doi.org/10.1086/650581.PubMedCrossRef

34.

Wong CM, Yang L, Chan KP, Chan WM, Song L, Lai HK, et al. Cigarette smoking as a risk factor for influenza-associated mortality: evidence from an elderly cohort. Influenza Other Respir Viruses. 2013;7:531–9 https://doi.org/10.1111/j.1750-2659.2012.00411.x.PubMedCrossRef

35.

Hennessy TW, Bruden D, Castrodale L, Komatsu K, Erhart LM, Thompson D, et al. A case-control study of risk factors for death from 2009 pandemic influenza A(H1N1): is American Indian racial status an independent risk factor? Epidemiol Infect. 2016;144:315–24 https://doi.org/10.1017/S0950268815001211.PubMedCrossRef

36.

Han L, Ran J, Mak YW, Suen LK, Lee PH, Peiris JSM, et al. Smoking and influenza-associated morbidity and mortality: a systematic review and meta-analysis. Epidemiology. 2019;30:405–17 https://doi.org/10.1097/EDE.0000000000000984.PubMedCrossRef

37.

Kulkarni R, Rampersaud R, Aguilar JL, Randis TM, Kreindler JL, Ratner AJ. Cigarette smoke inhibits airway epithelial cell innate immune responses to bacteria. Infect Immun. 2010;78:2146–52 https://doi.org/10.1128/IAI.01410-09.PubMedPubMedCentralCrossRef

38.

Amatngalim GD, Broekman W, Daniel NM, van der Vlugt LE, van Schadewijk A, Taube C, et al. Cigarette smoke modulates repair and innate immunity following injury to airway epithelial cells. PLoS One. 2016;11:e0166255 https://doi.org/10.1371/journal.pone.0166255.PubMedPubMedCentralCrossRef

39.

Wu W, Zhang W, Booth JL, Hutchings DC, Wang X, White VL, et al. Human primary airway epithelial cells isolated from active smokers have epigenetically impaired antiviral responses. Respir Res. 2016;17:111 https://doi.org/10.1186/s12931-016-0428-2.PubMedPubMedCentralCrossRef

40.

Muthuri SG, Venkatesan S, Myles PR, Leonardi-Bee J, Lim WS, Al Mamun A, et al. Impact of neuraminidase inhibitors on influenza A(H1N1)pdm09-related pneumonia: an individual participant data meta-analysis. Influenza Other Respir Viruses. 2016;10:192–204 https://doi.org/10.1111/irv.12363.PubMedPubMedCentralCrossRef

41.

Louie JK, Yang S, Acosta M, Yen C, Samuel MC, Schechter R, et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis. 2012;55:1198–204 https://doi.org/10.1093/cid/cis636.PubMedCrossRef

42.

Mertz D, Geraci J, Winkup J, Gessner BD, Ortiz JR, Loeb M. Pregnancy as a risk factor for severe outcomes from influenza virus infection: a systematic review and meta-analysis of observational studies. Vaccine. 2017;35:521–8 https://doi.org/10.1016/j.vaccine.2016.12.012.PubMedPubMedCentralCrossRef

43.

Coleman BL, Fadel SA, Fitzpatrick T, Thomas SM. Risk factors for serious outcomes associated with influenza illness in high- versus low- and middle-income countries: systematic literature review and meta-analysis. Influenza Other Respir Viruses. 2018;12:22–9 https://doi.org/10.1111/irv.12504.PubMedCrossRef

44.

MacIntyre CR, Chughtai AA, Barnes M, Ridda I, Seale H, Toms R, et al. The role of pneumonia and secondary bacterial infection in fatal and serious outcomes of pandemic influenza a(H1N1)pdm09. BMC Infect Dis. 2018;18:637 https://doi.org/10.1186/s12879-018-3548-0.PubMedPubMedCentralCrossRef

45.

Luyt CE, Rice TW. Co-infection in severe influenza: a new epidemiology? Intensive Care Med. 2017;43:107–9 https://doi.org/10.1007/s00134-016-4597-8.PubMedCrossRef

46.

Kossyvakis A, Mentis AA, Tryfinopoulou K, Pogka V, Kalliaropoulos A, et al. Antiviral susceptibility profile of influenza A viruses; keep an eye on immunocompromised patients under prolonged treatment. Eur J Clin Microbiol Infect Dis. 2017;36:361–71 https://doi.org/10.1007/s10096-016-2809-3.PubMedCrossRef

47.

Ison MG. Influenza prevention and treatment in transplant recipients and immunocompromised hosts. Influenza Other Respir Viruses Suppl. 2013;3:60–6 https://doi.org/10.1111/irv.12170.CrossRef

Title: FluA-p score: a novel prediction rule for mortality in influenza A-related pneumonia patients
Authors: Liang Chen
Xiudi Han
Yan Li Li
Chunxiao Zhang
Xiqian Xing
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Pneumonia
Influenza
Published in: Respiratory Research / Issue 1/2020
Electronic ISSN: 1465-993X
DOI: https://doi.org/10.1186/s12931-020-01379-z

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Lung volume dependence of respiratory function in rodent models of diabetes mellitus

Salbutamol use in relation to maintenance bronchodilator efficacy in COPD: a prospective subgroup analysis of the EMAX trial

Extracellular vesicles: novel communicators in lung diseases

Effects of prostaglandin E1 nebulization of ventilated lung under 60%O2 one lung ventilation on patients’ oxygenation and oxidative stress: a randomised controlled trial

Suppressed nuclear factor-kappa B alleviates lipopolysaccharide-induced acute lung injury through downregulation of CXCR4 mediated by microRNA-194

Respond to the letter to the editor by Van’t Hul et al. regarding the published manuscript “can do, don’t do” are not the lazy ones: a longitudinal study on physical functioning in patients with COPD” by Sievi et al.(1)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage